Acute liver failure (ALF) is a rare but life-threatening condition with high mortality. Despite advances in supportive care and liver transplantation, prognosis varies significantly across etiologies, particularly in patients with indeterminate causes. This study aims to investigate the dynamic changes of clinical and biochemical indicators, identify potential etiologies-especially in indeterminate ALF-and evaluate prognostic risk factors. A dynamic prediction model will be developed to optimize clinical decision-making, including liver transplantation timing. Both retrospective and prospective cohorts will be included. Multi-omics analyses (including transcriptomics, proteomics, metabolomics, and metagenomic sequencing) will be performed on liver tissue and biological samples to explore disease mechanisms and etiology.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Overall Survival
Timeframe: Up to 3 years after enrollment (every 3 months during the first year, then annually until year 3)
Transplant-Free Survival
Timeframe: Up to 3 years after enrollment (every 3 months during the first year, then annually until year 3)
Liver Transplantation Rate
Timeframe: Up to 3 years after enrollment (every 3 months during the first year, then annually until year 3